Physician profile
Lindsey Ribel
NPI 1043879158
$425.16
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.64 · 2023: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.48 | 2023 | Jardiance |
| Novo Nordisk INC | $72.21 | 2023 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $59.75 | 2023 | Mounjaro |
| Abbvie INC. | $51.33 | 2022-2023 | |
| Pfizer INC. | $27.14 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $23.29 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $16.96 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2023 | |
| Merck Sharp & Dohme LLC | $15.11 | 2023 | Varivax, Vaxneuvance, Proquad |
| Amgen INC. | $14.22 | 2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $13.44 | 2023 | Farxiga |
| Exact Sciences Corporation | $13.40 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Ribel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.